{"id":743,"date":"2026-05-29T00:45:32","date_gmt":"2026-05-29T04:45:32","guid":{"rendered":"https:\/\/www.durhampeptides.ca\/post\/what-is-kpv-research-overview"},"modified":"2026-09-26T20:03:11","modified_gmt":"2026-09-27T00:03:11","slug":"what-is-kpv-research-overview","status":"publish","type":"post","link":"https:\/\/www.durhampeptides.ca\/fr\/post\/what-is-kpv-research-overview","title":{"rendered":"What Is KPV? A Research Overview of the Anti-Inflammatory Tripeptide"},"content":{"rendered":"<figure><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-192\" src=\"https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/Klow-80mg-banner-image.png\" alt=\"KPV Lys-Pro-Val tripeptide alpha-MSH anti-inflammatory gut skin research Durham Peptides Canada\" width=\"1536\" height=\"1024\" srcset=\"https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/Klow-80mg-banner-image.png 1536w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/Klow-80mg-banner-image-300x200.webp 300w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/Klow-80mg-banner-image-1024x683.webp 1024w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/Klow-80mg-banner-image-768x512.webp 768w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/Klow-80mg-banner-image-800x533.webp 800w\" sizes=\"(max-width: 1536px) 100vw, 1536px\" \/><\/figure>\n<p>KPV Lys-Pro-Val tripeptide alpha-MSH anti-inflammatory gut skin research Durham Peptides Canada<\/p>\n<p><\/p>\n<p>KPV is one of the smallest peptides in the entire research peptide field \u2014 just three amino acids \u2014 and one of the more mechanistically distinct. Where most anti-inflammatory research peptides act through tissue-repair or immune-modulating pathways, KPV's research story traces back to a much larger molecule: it's the C-terminal fragment of <strong>\u03b1-<\/strong><\/p>\n<p><strong>MSH (alpha-melanocyte-stimulating hormone)<\/strong>, and it has been studied for retaining the anti-inflammatory properties of the parent hormone without the melanocortin-receptor-mediated pigmentation effects. That separation is what makes KPV a focused research tool rather than a general signaling peptide.<\/p>\n<p><\/p>\n<p>This article is a research-focused overview of KPV \u2014 what it is, the \u03b1-MSH biology that produced it, the gut and skin research literature that defines its profile, and how it fits the Durham Peptides catalog as a standalone compound and in the KLOW blend. For the existing KLOW-context coverage, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/what-is-kpv\/\" target=\"_blank\">What Is KPV? The Anti-Inflammatory Tripeptide in the KLOW Blend<\/a><\/u>; this post focuses on KPV as a standalone research compound with emphasis on the gut and skin literature. Nothing here is medical, dosing, or therapeutic guidance.<\/p>\n<p><\/p>\n<p><strong>The \u03b1-MSH Connection<\/strong><\/p>\n<p><\/p>\n<p>\u03b1-MSH (alpha-melanocyte-stimulating hormone) is a 13-amino-acid peptide hormone with two notable properties: it's a potent regulator of melanocyte activity (the basis of its name), and it has well-documented anti-inflammatory activity. The challenge for research has been that full-length \u03b1-MSH carries both effects together \u2014 the anti-inflammatory signaling alongside the melanocortin-receptor activity.<\/p>\n<p><\/p>\n<p>KPV \u2014 Lys-Pro-Val, the C-terminal tripeptide of \u03b1-MSH \u2014 was identified as the fragment that <strong>retains much of the anti-inflammatory activity<\/strong> of the parent hormone while not driving the melanocortin-receptor-mediated pigmentation effects in the same way. That separation has made KPV a research tool for studying anti-inflammatory pathways in isolation from the broader \u03b1-MSH biology.<\/p>\n<p><\/p>\n<p><strong>The Molecular Basics<\/strong><\/p>\n<p><\/p>\n<p>Durham Peptides' <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/kpv-10mg\/\" target=\"_blank\">KPV 10mg<\/a><\/u> is a short, well-characterized tripeptide:<\/p>\n<ul><li><strong>Sequence:<\/strong> Lys-Pro-Val (H-Lys-Pro-Val-OH)<\/li><li><strong>Molecular formula:<\/strong> C\u2081\u2086H\u2083\u2080N\u2084O\u2084<\/li><li><strong>Molecular weight:<\/strong> ~342.4 g\/mol<\/li><li><strong>CAS number:<\/strong> 67727-97-3<\/li><\/ul>\n<p><\/p>\n<p>At three amino acids, KPV is among the smallest research peptides \u2014 smaller than the tripeptide-copper complex <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/ghk-cu\/\" target=\"_blank\">GHK-Cu<\/a><\/u> once the copper is set aside, and dramatically smaller than peptides like <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/tb-500-10mg\/\" target=\"_blank\">TB-500<\/a><\/u> (43 amino acids). Its small size is also part of why it has been studied for oral bioavailability in some research models \u2014 a property that distinguishes it from the larger peptides in the category.<\/p>\n<p><\/p>\n<p><strong>Research Area 1: Inflammatory Bowel Research<\/strong><\/p>\n<p><\/p>\n<p>The single most-developed area of KPV research is in <strong>inflammatory bowel<\/strong> models. KPV has been studied extensively in models of colitis (particularly DSS- and TNBS-induced colitis in animal models), where research has examined its investigated effects on:<\/p>\n<ul><li><strong>Pro-inflammatory cytokine reduction<\/strong> \u2014 including TNF-\u03b1, IL-1\u03b2, IL-6, and IL-8 in gut tissue<\/li><li><strong>NF-\u03baB pathway modulation<\/strong> \u2014 a central inflammatory transcription factor<\/li><li><strong>Colon tissue inflammation markers<\/strong> \u2014 including epithelial damage and immune cell infiltration<\/li><li><strong>Gut barrier function<\/strong> \u2014 including studies of intestinal permeability in inflammatory models<\/li><\/ul>\n<p><\/p>\n<p>Notably, KPV has been studied for uptake via the <strong>PepT1 transporter<\/strong> in intestinal epithelial cells, which has been examined as a mechanism for its localized gut activity. This gut-research literature is the foundation of KPV's research reputation.<\/p>\n<p><\/p>\n<p><strong>Research Area 2: Skin and Dermatological Research<\/strong><\/p>\n<p><\/p>\n<p>KPV's \u03b1-MSH heritage also places it in dermatological research, where it has been studied in models of:<\/p>\n<ul><li><strong>Allergic and contact dermatitis<\/strong> \u2014 including investigated effects on inflammation in skin-irritation models<\/li><li><strong>UV-induced inflammation<\/strong> \u2014 given \u03b1-MSH's relationship to skin biology<\/li><li><strong>Mast cell activity<\/strong> \u2014 relevant to allergic and inflammatory skin responses<\/li><li><strong>Wound and skin barrier research<\/strong> \u2014 overlapping with the broader tissue-repair literature<\/li><\/ul>\n<p><\/p>\n<p>This skin angle is part of why KPV is studied alongside <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/ghk-cu\/\" target=\"_blank\">GHK-Cu<\/a><\/u> in skin-research contexts and appears in the KLOW four-peptide formulation. For the broader skin-research landscape, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/peptide-research-skin-health\/\" target=\"_blank\">Peptide Research for Skin Health: GHK-Cu, KPV, BPC-157<\/a><\/u>.<\/p>\n<p><\/p>\n<p><strong>Research Area 3: Systemic and Allergic Inflammation Models<\/strong><\/p>\n<p><\/p>\n<p>Beyond gut and skin, KPV has been studied in broader inflammatory and allergic models \u2014 including airway inflammation, food-allergy research, and systemic cytokine modulation. The research thread here is that KPV's anti-inflammatory activity, derived from the \u03b1-MSH lineage, has been examined across multiple tissues and inflammation types rather than being narrowly tissue-specific.<\/p>\n<p><\/p>\n<p><strong>Where KPV Fits the Anti-Inflammatory Peptide Category<\/strong><\/p>\n<p><\/p>\n<p>KPV sits in a small but distinct category of anti-inflammatory research peptides. Its mechanism is different from the others Durham Peptides carries:<\/p>\n<ul><li><strong>KPV<\/strong> \u2192 \u03b1-MSH-derived anti-inflammatory; NF-\u03baB and cytokine modulation<\/li><li><u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/bpc-157\/\" target=\"_blank\"><strong>BPC-157<\/strong><\/a><\/u> \u2192 tissue repair with anti-inflammatory threads; angiogenesis and gut protection<\/li><li><u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/ghk-cu\/\" target=\"_blank\"><strong>GHK-Cu<\/strong><\/a><\/u> \u2192 copper-peptide gene-expression modulation including inflammatory pathways<\/li><\/ul>\n<p><\/p>\n<p>For the head-to-head with BPC-157 in gut research specifically, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/kpv-vs-bpc-157-gut-research\/\" target=\"_blank\">KPV vs BPC-157 for Gut Research<\/a><\/u>. For the category overview, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/anti-inflammatory-peptides-research-overview\/\" target=\"_blank\">Anti-Inflammatory Peptides Research Overview<\/a><\/u>.<\/p>\n<p><\/p>\n<p><strong>KPV in the KLOW Blend<\/strong><\/p>\n<p><\/p>\n<p>KPV is the fourth peptide that distinguishes the <strong>KLOW blend<\/strong> from the GLOW blend. KLOW = KPV + GHK-Cu + BPC-157 + TB-500, where KPV adds dedicated anti-inflammatory signaling to the base three-peptide skin-and-recovery formulation. For the comparison, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/glow-vs-klow\/\" target=\"_blank\">GLOW vs KLOW<\/a><\/u> et <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/klow-blend-vs-glow-blend-comparison\/\" target=\"_blank\">KLOW Blend vs GLOW Blend<\/a><\/u>.<\/p>\n<p><\/p>\n<p><strong>Quality and Storage<\/strong><\/p>\n<p><\/p>\n<p>KPV is supplied as a lyophilized peptide, Janoshik-verified to \u226599% purity by HPLC with mass-spec identity confirmation, 100% synthetically manufactured (vegan). Storage: 2\u20138\u00b0C short-term, -20\u00b0C long-term, protected from light and moisture; reconstitute in <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/bacteriostatic-water-10ml\/\" target=\"_blank\">eau bact\u00e9riostatique<\/a><\/u>. See <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/how-to-read-janoshik-coa\/\" target=\"_blank\">How to Read a Janoshik COA<\/a><\/u>.<\/p>\n<p><\/p>\n<p><strong>Questions fr\u00e9quentes<\/strong><\/p>\n<p><\/p>\n<p><strong>What is KPV?<\/strong> A synthetic tripeptide (Lys-Pro-Val) derived from the C-terminal sequence of \u03b1-MSH, studied for anti-inflammatory activity in gut, skin, and systemic research models.<\/p>\n<p><\/p>\n<p><strong>Why is KPV studied separately from \u03b1-MSH?<\/strong> Because the tripeptide fragment retains much of the anti-inflammatory activity of the parent hormone while not driving the melanocortin-receptor-mediated pigmentation effects in the same way \u2014 useful for studying inflammation in isolation.<\/p>\n<p><\/p>\n<p><strong>What is KPV studied for in research?<\/strong> Inflammatory bowel models (DSS\/TNBS colitis), skin and dermatological inflammation, NF-\u03baB modulation, cytokine reduction, and gut barrier function.<\/p>\n<p><\/p>\n<p><strong>Is KPV the same as \u03b1-MSH?<\/strong> No \u2014 KPV is a three-amino-acid fragment (the C-terminal portion) of the full 13-amino-acid \u03b1-MSH hormone, studied for the anti-inflammatory subset of \u03b1-MSH's activity.<\/p>\n<p><\/p>\n<p><strong>How does KPV differ from BPC-157 in gut research?<\/strong> KPV is studied through \u03b1-MSH-derived anti-inflammatory pathways (NF-\u03baB, cytokines); BPC-157 is studied through tissue-repair pathways including angiogenesis and gut-lining protection. See <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/kpv-vs-bpc-157-gut-research\/\" target=\"_blank\">KPV vs BPC-157 for Gut Research<\/a><\/u>.<\/p>\n<p><\/p>\n<p><strong>What is the KLOW blend?<\/strong> KLOW = KPV + GHK-Cu + BPC-157 + TB-500. The KPV addition extends the GLOW skin-and-recovery base with dedicated anti-inflammatory research signaling.<\/p>\n<p><\/p>\n<p><strong>Final Thoughts<\/strong><\/p>\n<p><\/p>\n<p>KPV occupies a small but distinctive corner of anti-inflammatory peptide research \u2014 a three-amino-acid fragment carrying the anti-inflammatory dimension of \u03b1-MSH into a focused research tool. Its gut and skin literature, mechanism through cytokine and NF-\u03baB modulation, and role in the KLOW blend make it a meaningful complement to the broader recovery and anti-aging peptide categories.<\/p>\n<p><\/p>\n<p>For the BPC-157 comparison, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/kpv-vs-bpc-157-gut-research\/\" target=\"_blank\">KPV vs BPC-157 for Gut Research<\/a><\/u>; for the KLOW context, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/glow-vs-klow\/\" target=\"_blank\">GLOW vs KLOW<\/a><\/u>. Browse the full catalog at <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/category\/all-products\/\" target=\"_blank\" rel=\"noreferrer\">durhampeptides.ca\/category\/all-products<\/a><\/u> \u2014 see the <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/kpv-10mg\/\" target=\"_blank\">KPV 10mg product page<\/a><\/u>.<\/p>\n<p><\/p>\n<p><strong>Selected Research References<\/strong><\/p>\n<p><\/p>\n<ol><li>Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. <em>Gastroenterology<\/em>. 2008;134(1):166-178. <u><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/18061177\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/18061177\/<\/a><\/u><\/li><li>Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-Derived Tripeptide KPV Has Anti-Inflammatory Potential in Murine Models of Inflammatory Bowel Disease. <em>Inflammatory Bowel Diseases<\/em>. 2008;14(3):324-331. <u><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/18092346\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/18092346\/<\/a><\/u><\/li><li>Hiltz ME, Lipton JM. Antiinflammatory Activity of a COOH-Terminal Fragment of the Neuropeptide Alpha-MSH. <em>FASEB Journal<\/em>. 1989;3(11):2282-2284. <u><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/2550304\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/2550304\/<\/a><\/u><\/li><li>Catania A, Lonati C, Sordi A, Carlin A, Leonardi P, Gatti S. The Melanocortin System in Control of Inflammation. <em>The Scientific World Journal<\/em>. 2010;10:1840-1853. <u><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20852829\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/20852829\/<\/a><\/u><\/li><\/ol>\n<p><\/p>\n<p><em>All products sold by Durham Peptides are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.<\/em><\/p>","protected":false},"excerpt":{"rendered":"KPV Lys-Pro-Val tripeptide alpha-MSH anti-inflammatory gut skin research Durham Peptides Canada KPV is one of the smallest peptides in the entire research peptide field \u2014 just three amino acids \u2014 and one of the more mechanistically distinct. Where most anti-inflammatory research peptides act through tissue-repair or immune-modulating pathways, KPV's research story traces back to a much larger molecule: it's the C-terminal fragment of \u03b1- MSH (alpha-melanocyte-stimulating hormone), and it has...","protected":false},"author":1,"featured_media":192,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55],"tags":[],"class_list":["post-743","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research-science"],"_links":{"self":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/comments?post=743"}],"version-history":[{"count":1,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/743\/revisions"}],"predecessor-version":[{"id":1084,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/743\/revisions\/1084"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/media\/192"}],"wp:attachment":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/media?parent=743"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/categories?post=743"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/tags?post=743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}